Accumulation Zone

I like to think that’s exactly what’s creating the opportunity here. As always, I try to stay unbiased with new information coming out and assess, “Does it damage the original thesis or strengthen it”? The sentiment feels disconnected from what we’re seeing commercially. Maybe the market is focused on near term execution and competitive fears, while I’m looking at where this space could be 5-10 years from now. Either way, it’s always refreshing getting insight from someone who actually prescribes these therapies and sees the patient side of the equation every day. Invaluable insight Doc. Keep up the hard work. I love the content and your perspective.

Sounds like you have strong reasoned conviction, wishing you the best!! I agree with the TAM expanding, I’ve also alluded to similar points on my posts. I actually use a whole range of novo products at work already eg. Novomix, novorapid insulin injections for my patients. I’m excited by the prospect of prescribing Wegovy pill to my patients too, and potentially cagrisema for T2D patients with obesity too given the incredible benefits of semaglutide. Definitely a massive role for Novo in the expanding obesity TAM. I don’t understand the negative sentiment from the market however. Sometimes fundamentals can be in place, but the market can be irrational. Market doesn’t behave logically. At times, balance sheet can also look handsome but the market doesn’t give a toss (eg. DUOL!!)

Added more $NVO today. When I look at the next 5-10 years, I see A global obesity market that keeps getting larger. A pipeline that extends beyond today’s products. Yet the stock trades as if growth is over. That’s the disconnect I’m buying.

@TheStockerMan Yessir exactly. Unfolding in front of us.

@AccumulationZ The Amazon of healthcare

This company was never meant to stay a US telehealth app selling a few medications. The real vision is to become a global, vertically integrated consumer healthcare platform. Global expansion is already happening. Through Eucalyptus, $HIMS is gaining exposure to markets like Canada, the UK, Germany, Australia and Japan instead of building every operation from zero. Then come peptides. $HIMS acquired a US peptide facility, giving the company more control over manufacturing, supply, personalization and potentially margins. Peptides could eventually expand the platform into areas like metabolic health, hormonal health, recovery and longevity, depending on regulatory and clinical progress. The thesis is becoming clearer: Expand globally. Enter more healthcare categories. Own more of the supply chain. Use AI and data to personalize treatment. Build long-term relationships with customers across multiple parts of their health. The market keeps judging $HIMS based on short-term GLP-1 noise. I’m focused on what this platform could become over the next five to ten years. This is exactly why $HIMS remains one of my next high-conviction growth bets.

@EnergyWaterFood The oral market is still in its infancy too. If adoption continues at this pace, I wouldn’t be surprised to see estimates revised higher again over the next few years.

@AccumulationZ Goldman admits they have been way to conservative on NVO's Wegovy Pill, raising its 2030 oral obesity market share from 16% to 38% and more than doubled its peak sales estimate from $8B to $17.4B. Just the start of many more admissions to come.

Fair point Doc. The S&P is definitely the more predictable choice. My view is that $NVO valuation already reflects a lot of bad news, while the obesity market is still expanding rapidly. If that thesis plays out, I believe the upside from today’s price is far greater than what I’d expect from the S&P over the next few years. Once again dependent on the thesis playing out, but that’s a bet I’m willing to take.

@AccumulationZ Looks really undervalued to me! Horrible opportunity cost though, had that money been in an index fund the returns would have been more predictable Do you think the stocks valuation would increase more than the S&P over the next 2-3 years?

@KickWestra Especially at these levels with a solid dividend. I plan to continue accumulating and reinvesting dividends until the market figures it out.

@AccumulationZ It's insane how undervalued it is vs the market opportunity that's out there.

The 2026 Mid-Term Elections are fast approaching. Projected political ad spend: $10B - $11B That's a massive amount of money flowing into digital advertising, streaming, and local media. My top beneficiaries: $ZETA - $META - $GOOGL - $ZETA

@StockChaser_ $NVO is trading at 9.8x earnings despite Oral Wegovy becoming one of the most successful drug launches in history. I’d go with undervalued.

Is $NVO undervalued or is the market correctly pricing in future weakness? The Wegovy pill launch has been the best GLP-1 drug launch: • 3M+ US prescriptions in 5 months • 80%+ of new prescriptions came from patients new to GLP-1s The pill is expanding the market, not simply cannibalizing injections However, at the same time: • Weak 2026 guide • CagriSema fell short of Lilly’s tirzepatide • $LLY continues gaining competitive ground At 9.8x PE, $NVO looks historically cheap Is this a good entry or a value trap like PainPal?

@VJNCapital $MSFT got stronger while valuation became cheaper. Fully scaled into my position. If we go lower, I will continue to add.

$MSFT still trading at the same valuation as the Covid lows At the time revenue was growing 13% Now it is growing at 18%

@DoubleSpeakPod @TheRonnieVShow Completely agree. Best of luck to you my friend. 🤝🏼

@AccumulationZ @TheRonnieVShow I added 13k to my position today. Weekly chart just looks too good, we’ll see

The hardest lesson are learned through failure. Retail is selling. Hedge Funds are buying. $ZETA

@Aktieland Couldn’t agree more. Fundamentals and price are showing a huge disconnect. Once sentiment starts to shift, we will be in for a ride.

Adj. for dividends, $NVO trades at the same level as August 4, 2021 — before the obesity market started. Since then, Novo Nordisk has built a dominant position in obesity treatment, expanded globally & increased earning The market can be irrational for a while #NovoNordisk

@Investinc_Intel Yeah i’m not sure what the bears see lmao. $HIMS has a very bright future.

$HIMS IS A FUTURE 100B+ MCAP

@OkaneInfinite I agree most people would rather take a pill than a weekly injection. Early signs point to market expansion.

@AccumulationZ The pill will eat into injections. Probably has already started. Nobidy wants a shot for weight loss. The Wegovy pill is the best diet pill.

The obesity market is still expanding, oral Wegovy is opening the door to new patients, and prescription growth continues to accelerate. $NVO

@ModernDayInves @pulseandprofit Right there with you. Feels like one of the most obvious buys in the market.

Are me and @pulseandprofit the only bullish accounts on $MSFT? Anyone else out there?

@Matkinvest Just gave the video a watch. Super insightful, easy to digest all of the information. The TAM continues expanding with millions untreated. The future is bright for $NVO

I just posted a video about the recent developments at $NVO. I think the market is structurally wrong in its assesement of the company, and this video explores why: We Need To Talk About Novo Nordisk youtu.be/Ay-irYV3CTg

Another great post Doc! The GI tolerability concerns are real and shouldn’t be ignored. At the same time, achieving meaningful HbA1c reductions alongside weight loss in a difficult to treat population is an impressive signal. For me, $NVO continues to show depth beyond any single asset. Whether it’s Amycretin, Oral Wegovy, or other combination therapies, the pipeline keeps generating new shots on goal. Looking forward to seeing how the Phase 3 data develops.

🔔Don't sleep on Amycretin. Patients with obesity and type 2 diabetes are notoriously difficult to treat for weight loss due to insulin resistance. Yet Amycretin delivered statistically significant HbA1c reductions & up to ~14.6% weight loss @ 36 weeks. I'm excited by it! 🧵

@RockBolig @fdzmurillo The obesity and diabetes market is massive enough for multiple winners, and $NVO pipeline remains deeper than many give it credit for. One of the main reasons i’ve accumulated despite the negative sentiment around Novo

$NVO $LLY Zenagamtide just delivered what is truly the most impressive diabetes data ever. 14.6% weight loss in type 2 diabetes after only 36 weeks, no weight-loss plateau observed, and 89% of patients achieved HbA1c below 7%. Compared with Eli Lilly these results look highly competitive despite much shorter exposure to the highest dose. If phase 3 confirms these findings, Novo may have a therapy that surpasses Lilly’s current offerings in both glucose control and weight reduction. The obesity and diabetes race is far from over. Let’s go $NVO 💪